Published online before print December 29, 2003, doi: 10.1161/01.CIR.0000109642.27985.FA
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:262-268.)
© 2004 American Heart Association, Inc.
Basic Science Reports |
Targeted Overexpression of Noncleavable and Secreted Forms of Tumor Necrosis Factor Provokes Disparate Cardiac Phenotypes
From the Winters Center for Heart Failure Research (A.D., Z.D., N.S., D.L.M.), Medical Service Care Line (S.N., G.D., B.A.C.), Houston VAMC, Baylor College of Medicine and the Methodist Hospital, Houston, Tex; and Department of Surgery (E.M.W., F.G.S.), Cardiothoracic Research, Medical University of South Carolina, Charleston, SC.
Correspondence to Douglas L. Mann, MD, Winters Center for Heart Failure Research, MS 524, 6565 Fannin, Houston, TX 77030. E-mail dmann{at}bcm.tmc.edu
Received July 21, 2003; revision received September 11, 2003; accepted September 22, 2003.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Background— Recent studies suggest that posttranslation processing or "shedding" (ie, secretion) of tumor necrosis factor (TNF) by tumor necrosis factor-
converting enzyme (TACE) may contribute to the left ventricular (LV) remodeling that occurs in the failing human heart. Methods and Results— To address the functional significance of TNF shedding, we generated lines of transgenic mice with targeted overexpression of secreted wild-type (MHCsTNF2) TNF and overexpression of a mutated noncleavable transmembrane form of TNF (MHCmTNF). Both lines of mice had overlapping levels of myocardial TNF protein; however, the phenotypes of the MHCsTNF2 and MHCmTNF mice were strikingly disparate. Whereas the MHCmTNF mice developed a concentric LV hypertrophy phenotype, the MHCsTNF2 mice developed a dilated LV phenotype. The fibrillar collagen weave in MHCmTNF mice with concentric hypertrophy was characterized by thick collagen fibrils and increased collagen content, whereas the fibrillar collagen weave in the MHCsTNF2 mice with LV dilation was characterized by a diminished collagen content. Inhibition of matrix metalloproteinases with a broad-based matrix metalloproteinase inhibitor prevented LV dilation in the MHCsTNF2 mice.
Conclusions— These findings suggest that posttranslational processing of TNF, as opposed to TNF expression per se, is responsible for the adverse cardiac remodeling that occurs after sustained TNF overexpression.
Key Words: hypertrophy • remodeling • metalloproteinases
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Recent studies from this and other laboratories have suggested that the expression of tumor necrosis factor (TNF) in the heart confers cytoprotective responses (reviewed in Mann1). These salutary effects of TNF have been difficult to reconcile with the known untoward effects of sustained TNF expression, which include left ventricular (LV) dysfunction, extracellular matrix degradation, and LV remodeling, any or all of which may contribute directly to the development of cardiac decompensation (reviewed in Mann2). Relevant to the present discussion is the observation that TNF is initially synthesized as a 26-kDa type II transmembrane protein that is subsequently cleaved (ie, secreted) by a membrane-bound enzyme termed TNF-
converting enzyme (TACE).3 The resultant 17-kDa TNF monomer that is "shed" from the cell-surface membrane subsequently assembles as a biologically active homotrimer that initiates cell signaling.3 Noting that the membrane-bound and secreted forms of TNF have distinctly different biological actions4 and that TACE is upregulated in the heart in pathophysiological contexts wherein LV dilation and dysfunction occur,5 we questioned whether posttranslation processing of TNF (ie, secretion) might contribute to the adverse cardiac remodeling that is observed after sustained TNF expression. In the present report, we compared a line of transgenic mice with targeted cardiac overexpression of a mutated form of TNF that lacks the TACE recognition site, and hence cannot be secreted, with a second line of mice with targeted cardiac overexpression of wild-type secreted TNF. |
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Generation and Characterization of MHCmTNF and MHCsTNF2 Transgenic Lines
Lines of transgenic mice with cardiac restricted overexpression of secretable TNF (referred to as MHCsTNF2 mice) and cardiac restricted overexpression of a mutated form of TNF that lacked the TACE recognition site (referred to as MHCmTNF mice) that is responsible for TNF shedding (secretion) were generated with the
-myosin heavy chain (MHC) promoter (a gift from Jeff Robbins, University of Cincinnati, Cincinnati, Ohio) to target TNF expression to the cardiac myocyte, as described previously.6 The TNF transgene that encoded wild-type secretable TNF contained an intact TACE recognition site, whereas the transgene coding for the noncleavable transmembrane form of TNF lacked the TACE recognition site (see Data Supplement). The generation and preliminary characterization of the MHCmTNF has been reported previously.7 Both the MHCmTNF and MHCsTNF2 mice were generated on an FVB background to facilitate comparison between lines of transgenic mice.
Characterization of Cardiac Phenotype in MHCmTNF and MHCsTNF2 Mice
Cardiac Phenotype and Morphology
Perfusion fixation and histological analysis of the hearts were performed as described (see Data Supplement).8 Myocyte length was measured on fixed isolated cardiac myocytes according to the method of Gerdes et al.9
Cardiac Structure and Hemodynamics
We used 2D-targeted M-mode echocardiography and simultaneous hemodynamic catheterization to characterize LV structure and hemodynamics, respectively, in male wild-type, MHCmTNF, and MHCsTNF2 mice.10 LV end-systolic and end-diastolic pressure were assessed with a 1.4F microtipped Millar catheter. LV end-systolic and end-diastolic wall stress were calculated with hemodynamic data and the assessments of end-systolic and end-diastolic LV wall thickness that were obtained from M-mode echocardiography.10
Myocardial Fibrillar Collagen
Scanning electron microscopy and picrosirius red staining were performed to examine myocardial fibrillar collagen, as described previously.6
Matrix Metalloproteinase Activity and Abundance
Matrix metalloproteinase (MMP) zymographic activity was measured in myocardial protein extracts (16 µg) with gelatin zymography.6 Purified gelatinase (MMP9; 0.125 mg/mL) and MMP2 (0.125 mg/mL) were used as standards. To measure MMP2 abundance (ie, the sum of latent and activated MMP2 species), the cardiac protein extracts were treated with p-aminophenylmercuric acetate (APMA), an organomercurial compound that activates MMPs. MMP2 abundance was then measured with an ELISA that measures levels of total activated MMP2 species (#RPN 2631, Amersham).
Expression of Tissue Inhibitor of Metalloproteinases Type 1
Tissue inhibitor of metalloproteinases type 1 (TIMP-1) levels were measured in myocardial extracts by ELISA (#RPN 2611, Amersham), as described previously.6
MMP Inhibition
To determine the effects of MMP inhibition on LV structure in MHCsTNF2 mice, we treated MHCsTNF2 mice with an MMP inhibitor (MMPi), PD 166793 (30 mg · kg-1 · d-1 PO in chow), from 3 to 6 weeks of age (n=13/group). Six-week-old wild-type mice (n=13) and 6 week-old MHCsTNF2 mice (n=11) fed normal chow were used as the appropriate controls. In preliminary dosing studies in this strain of mice, this dosing strategy resulted in steady state plasma levels of 33±2 µg/mL. This plasma level of PD 166793 exceeds the concentration necessary to inhibit all of the classes of MMPs. Importantly, PD 166973 has no effect on other metalloproteinases such as TACE. After the 3-week treatment period, the mice were anesthetized, and a precalibrated 4-electrode pressure sensor catheter (1.4F, Millar Instruments) was positioned in the LV. The catheter was interfaced to a Millar volumetric-conductance unit to compute absolute LV volumes in vivo, as described previously.11
Statistical Analysis
All values are expressed as mean±SEM. Two-way ANOVA was used to detect differences between MHCmTNF, MHCsTNF2, and wild-type mice for all parameters at the ages studied. Where appropriate, post hoc testing was performed with a Tukey test to detect differences between groups. Significant differences were said to exist at P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Characterization of MHCmTNF and MHCsTNF2 Mice
We obtained 5 heterozygous founder lines that harbored cardiac restricted overexpression of the wild-type secretable TNF transgene: s49 (6 copies), s112 (12 copies), s118 (32 copies), s121 (32 copies), and s122 (32 copies). Each of these lines developed a dilated cardiac phenotype (data not shown). The s49 line was selected for further characterization, insofar as the myocardial TNF protein levels overlapped those observed in a previously characterized MHCmTNF line of mice.7 The level of myocardial TNF protein in MHCmTNF mice was not significantly different (P=0.9) from that detected in MHCsTNF2 mice at 6 and 24 weeks of age (Figure 1A). As expected, myocardial TNF protein levels in both MHCmTNF and MHCsTNF2 mice were significantly greater (P<0.001) than those observed in age-matched wild-type mice. Western blot analysis cardiac extracts from MHCsTNF2 mice revealed a prominent 26-kDa band, corresponding to the transmembrane form of wild-type TNF, and a fainter band corresponding to the 17-kDa secreted form of TNF (Figure 1B). In contrast, cardiac extracts from MHCmTNF mice revealed a prominent 24-kDa band, corresponding to the noncleavable transmembrane form of TNF protein that lacked the TACE recognition site. We did not detect a 17-kDa band in the cardiac extracts from the MHCmTNF lines of mice. Plasma levels of circulating TNF were significantly (P<0.001) increased in MHCsTNF2 mice at 6 and 24 weeks of age (P<0.001) compared with MHCmTNF and wild-type mice at comparable ages (Figure 1C), whereas plasma TNF levels in MHCmTNF and wild-type mice were barely detectable and were not significantly different from each other (P=0.33).
|
Phenotypic Characterization of MHCmTNF and MHCsTNF2 Mice (6 Weeks)
Figure 2 shows that at 6 weeks of age, the MHCmTNF mice developed a concentric cardiac hypertrophic phenotype (Figures 2E and 2H), whereas the MHCsTNF2 mice developed a dilated cardiac phenotype (Figures 2F and 2I). Histological examination of hearts from the MHCmTNF (Figure 2K) and MHCsTNF2 (Figure 2L) mice showed a normal linear arrangement of myofibrils compared with wild-type mice (Figure 2J). There was no obvious myofibrillar disarray nor prominent interstitial infiltrating cells in any of the sections that were examined from the MHCmTNF and MHCsTNF2 mice.
|
Longitudinal Characterization of Cardiac Phenotype in MHCmTNF and MHCsTNF2 Mice (6 to 24 Weeks)
Figure 3 summarizes the longitudinal assessment of cardiac structure in the wild-type, MHCmTNF, and MHCsTNF2 mice. The heart-weight–to–body-weight ratios were significantly greater (P=0.002) in the MHCmTNF and MHCsTNF2 mice than in the wild-type mice at 6 and 24 weeks of age (Figure 3A). This increase in heart-weight–to–body-weight ratio in the MHCmTNF mice and the MHCsTNF2 mice was due, at least in part, to a significant (P<0.006) increase in LV mass-to–body-weight ratio in the MHCmTNF and MHCsTNF2 mice compared with the wild-type control mice (Figure 3B). However, the pattern of cardiac hypertrophy was different in the MHCmTNF and MHCsTNF2 mice. Consistent with the phenotypic appearance of the hearts presented in Figure 2, MHCmTNF mice developed a hypertrophic phenotype that was characterized by a significant (P<0.001) increase in LV wall thickness (ie, concentric hypertrophy) compared with wild-type mice (Figure 3C), whereas MHCsTNF2 mice developed a cardiac phenotype characterized by a significant (P<0.001) increase in LV volume compared with wild-type mice (Figure 3D). Importantly, the concentric hypertrophic phenotype of the MHCmTNF mice persisted from 6 to 24 weeks, as shown by the preserved increase in LV wall thickness, with no increase in LV end-diastolic volume (Figures 3C and 3D). Similarly, the dilated cardiac phenotype of the MHCsTNF2 mice was maintained, as demonstrated by the persistent (P<0.001) increase in LV volume at 6 to 24 weeks in the MHCsTNF2 mice compared with the wild-type and the MHCmTNF mice (Figure 3D).
|
Longitudinal Characterization of Myocardial Structure in MHCmTNF and MHCsTNF2 Mice (6 and 24 Weeks)
Cardiac Myocyte Hypertrophy
The cross-sectional area of myocytes from the hearts of MHCmTNF mice was significantly (P<0.05) greater in MHCmTNF mice at 6 and 24 weeks than in wild-type and MHCsTNF2 mice, whereas myocyte cross-sectional area was not significantly different (P>0.05) between MHCsTNF2 and wild-type control mice (Table 1). In contrast, myocyte cell length was significantly increased (P<0.05) in MHCsTNF2 mice at 6 and 24 weeks compared with both wild-type and MHCmTNF mice, whereas myocyte cell length was not significantly different (P=0.67) between MHCmTNF and wild-type mice (Table 1).
|
Myocardial Fibrillar Collagen
Figures 4B and 4E show that there was a loss of myocardial fibrillar collagen in the MHCsTNF2 mice at 6 and 24 weeks of age compared with age-matched wild-type controls. In contrast, myocardial sections taken from the MHCmTNF mice revealed a dense fibrillar collagen weave and a thickening of the fibrillar struts between myocytes (Figures 4C and 4F). To further characterize the time-dependent changes in fibrillar collagen content, we performed picrosirius red staining in the MHCsTNF2, MHCmTNF, and wild-type mice (n=5 to 6 hearts per time point). There was a significant (P=0.002) 
25% to 35% decrease in myocardial fibrillar collagen content in MHCsTNF mice compared with MHCmTNF and wild-type control mice (Figure 4G), which coincided with the qualitative changes in fibrillar collagen weave observed in the MHCsTNF2 mice (Figures 4B and 4E), whereas there was a significant (P<0.001) 35% to 40% increase in collagen content in the MHCmTNF mice at 6 and 24 weeks of age (compared with age-matched control mice), consistent with the qualitative assessment of fibrillar collagen in the MHCmTNF mice (Figures 4B and 4E).
|
Mechanism for the Disparate Cardiac Phenotypes in MHCmTNF and MHCsTNF2 Mice
Hemodynamic Assessment of MHCmTNF and MHCsTNF2 Mice
Peak LV systolic pressure was not significantly different between the MHCmTNF, MHCsTNF2, and wild-type mice (Table 2). Moreover, end-systolic wall stress was significantly less (P<0.05) in the MHCmTNF mice (25.99±1.5 g/cm2) than in either the MHCsTNF2 mice (31.10±1.2 g/cm2) or the wild-type mice (37.75±1.0 g/cm2). LV end-diastolic pressure was significantly (P<0.05) elevated in MHCsTNF2 compared with MHCmTNF and wild-type mice.
|
MMP Activity
As shown in the representative gelatin zymograms in Figure 5A, we observed lytic bands at 65 kDa (arrow) in all 3 lines of mice, suggestive of MMP2 activity. However, relative to wild-type mice and MHCmTNF mice, MMP activity was significantly greater (P<0.001 and P<0.02, respectively) in MHCsTNF2 mice at 6 weeks of age, coinciding with the decrease in fibrillar collagen content observed in these mice at this time point. There was, however, no significant (P=0.11) overall difference in MMP activity between wild-type and MHCmTNF mice. In addition, there was a striking decrease in MMP activity in MHCsTNF2 mice at 24 weeks of age (P=0.007 for 6 weeks versus 24 weeks), whereas MMP activity was not significantly different (P=0.32) in MHCmTNF mice from 6 to 24 weeks of age. To determine whether the changes in MMP activity observed in MHCsTNF2 mice were the result of changes in MMP2 abundance, we measured MMP2 abundance at 6 and 24 weeks of age. Figure 5C shows that there was a significant increase (P<0.001) in MMP2 abundance in both the MHCsTNF2 mice and the MHCmTNF mice compared with wild-type mice at 6 weeks of age. However, whereas MMP2 abundance decreased in MHCsTNF2 mice and was not significantly (P>0.4) different from wild-type mice at 24 weeks of age, MMP2 abundance remained increased in MHCmTNF mice and was significantly (P<0.001) greater than in wild-type mice at 24 weeks of age. Insofar as there was no significant difference in total MMP2 abundance between MHCmTNF and MHCsTNF2 hearts at 6 weeks (P=0.94), the increase in MMP2 zymographic activity in MHCsTNF2 mice suggests there was increased activation of MMP in these mice.
|
TIMP Levels
We next examined changes in TIMP-1 levels as a possible mechanism for the observed differences in MMP activity in the MHCmTNF and MHCsTNF2 mice. Figure 5D shows that relative to levels in wild-type mice, TIMP-1 levels were significantly lower in MHCsTNF2 and MHCmTNF mice at 6 weeks of age (P=0.04 and P=0.002, respectively). However, at 24 weeks of age, there was a significant (P=0.90) difference in TIMP-1 levels between MHCsTNF2, MHCmTNF, and wild-type mice.
MMP Inhibition
As shown in Table 3, treatment of MHCsTNF2 (n=13) mice with an MMPi from 3 to 6 weeks of age significantly (P<0.05) attenuated the degree of LV dilation compared with untreated MHCsTNF2 mice (n=13). Furthermore, attenuation of LV dilation was not the result of a decrease in afterload, insofar as the peak LV systolic pressures were not significantly different (P=0.27) in wild-type, MMPi, and MHCsTNF2 mice.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
This study, in which we compared lines of transgenic mice with targeted overexpression of secreted and transmembrane TNF, constitutes the initial demonstration that spatial localization of TNF within the heart provokes distinct but opposite patterns of cardiac hypertrophy. That is, mice with targeted overexpression of a transgene coding for noncleavable transmembrane TNF (MHCmTNF) develop a concentric LV hypertrophy phenotype (Figures 2, 3A, 3B, and 3
C), whereas mice with targeted overexpression of a transgene coding for secreted TNF (MHCsTNF2) develop a dilated LV hypertrophy phenotype (Figures 2, 3A, 3B, and 3D). Importantly, the disparate patterns of LV hypertrophy in MHCmTNF and MHCsTNF2 mice were not secondary to differences in myocardial TNF protein levels, which were not significantly different in the 2 lines of mice (Figure 1A). Moreover, the observed differences in cardiac phenotype did not appear to be the result of selective differences in LV afterload between the 2 models, insofar as peak LV end-systolic pressure was not significantly different in MHCmTNF and MHCsTNF2 mice (Table 2). Rather, the disparate patterns of LV cardiac hypertrophy in MHCmTNF and MHCsTNF2 mice were secondary to the manner in which the transmembrane and secreted forms of TNF selectively influenced remodeling of cardiac myocytes and the extracellular matrix. Whereas the fibrillar collagen weave in MHCmTNF mice was characterized by thick collagen fibrils (Figures 4C and 4F) and increased collagen content (Figure 4G), the fibrillar collagen weave in the mice that developed LV dilation (MHCsTNF2) was characterized by dissolution of the collagen weave (Figures 4B and 4E) and diminished collagen content (Figure 4G). To delineate the mechanisms that were responsible for the different patterns of extracellular matrix remodeling in the MHCmTNF and MHCsTNF2 mice, we asked whether there were differences in MMP activity and TIMP levels in the 2 lines of mice, insofar as previous observations from this and other laboratories have implicated time-dependent changes in the balance between MMP activity and TIMP activity as an important determinant of LV dilation.6,12 Consistent with our previous observations, we observed increased MMP abundance, increased MMP activity (Figures 5A and 5B), and decreased TIMP levels in the MHCsTNF2 mice at 6 weeks of age. Collectively, the increased levels of active MMP-2 determined by zymography coupled with the reduction in TIMP-1 levels would favor increased MMP activation within the myocardium and thereby accelerate degradation of the extracellular matrix in the MHCsTNF2 mice. Notably, the most remarkable change in MMP-2/TIMP-1 stoichiometry occurred at 6 weeks, which coincided with the significant increase in LV dilation in the MHCsTNF2 mice at this time point. Given the MMP2 abundance and that TIMP levels were not significantly different in the MHCmTNF and MHCsTNF2 mice, the increased MMP-2 activational state in the MHCsTNF2 mice was likely due to increased activation of 1 or more upstream proteases (eg, plasmin) or local MMP activational systems (eg, membrane-bound MMPs) that are known to activate MMPs. Although the potential reasons for this differential activation are not known, one plausible explanation is that transmembrane TNF is spatially constrained, whereas secretable TNF lacks spatial constraint and is able to activate upstream proteases in endothelial cells, smooth muscle cells, and fibroblasts, which in turn are capable of activating MMPs in a paracrine manner. The importance of MMP activation as a mechanism for LV dilation in the MHCsTNF2 mice was shown by studies in which an MMPi was sufficient to attenuate LV dilation in MHCsTNF2 mice (Table 3), consistent with previous reports that have shown that MMPi attenuates LV dilation in different heart failure models.13–15
|
Conclusions |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
The findings of the present study are compatible with the known pleiotropic effects of TNF and highlight the disparate roles that transmembrane and secreted TNF play in the heart. On a more basic level, these studies may also provide insight into the basic mechanisms that govern LV remodeling in the heart. That is, whereas previous studies have focused on changes in cardiac myocyte length as a primary determinant of LV remodeling, the results of the present study suggest that this view may be overly simplistic. The observation that LV dilation in MHCsTNF2 mice was dependent on permissive changes in MMP activity and TIMP levels that favored matrix degradation and was abrogated by MMP inhibition suggests that changes in myocyte length (hypertrophy) and myocardial fibrillar collagen content likely occur in tandem, as the ventricle dilates in response to changes in diastolic hemodynamic loading conditions. This in turn raises the intriguing, if not important, question of how these events are coordinated at the cellular and molecular level during cardiac remodeling. To this end, the transgenic mouse lines developed herein should provide us with useful model systems to begin to delineate the signaling events that govern the concurrent changes in myocyte growth and fibrillar collagen content during the important transition from concentric hypertrophy to dilated cardiomyopathy.
|
Acknowledgments |
|---|
This research was supported by research funds from the Veterans Administration and the National Institutes of Health (P50 HL-O6H and RO1 HL58081-01, RO1 HL61543-01, HL-42250-10/10). We thank Dr Mark Entman for his critical review of the manuscript.
|
Footnotes |
|---|
An online data supplement is available at http://www.circulationaha.org.
Guest Editor for this article was Wilson S. Colucci, MD, Boston University Medical Center, Boston, Mass.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
1. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol. 2003; 65: 81–101.[CrossRef][Medline] [Order article via Infotrieve]
2. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002; 91: 988–998.
3. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor- from cells. Nature. 1997; 385: 729–733.[CrossRef][Medline]
[Order article via Infotrieve]
4. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995; 83: 793–802.[CrossRef][Medline] [Order article via Infotrieve]
5. Satoh M, Nakamura M, Saitoh H, et al. Tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human dilated cardiomyopathy. Circulation. 1999; 99: 3260–3265.
6. Sivasubramanian N, Coker ML, Kurrelmeyer K, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001; 2001: 826–831.
7. Dibbs ZI, Diwan A, Nemoto S, et al. Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation. 2003; 108: 1002–1008.
8. Bozkurt B, Kribbs S, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor- promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998; 97: 1382–1391.
9. Gerdes AM, Onodera T, Tamura T, et al. New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. J Card Fail. 1998; 4: 343–348.[CrossRef][Medline] [Order article via Infotrieve]
10. Nemoto S, Vallejo JG, Knuefermann P, et al. Escherichia coli lipopolysaccharide-induced left ventricular dysfunction: the role of toll-like receptor-4 in the adult mammalian heart. Am J Physiol. 2002; 282: H2316–H2323.
11. Roten L, Nemoto S, Simsic J, et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol. 2000; 32: 109–120.[CrossRef][Medline] [Order article via Infotrieve]
12. Li YY, Feng YQ, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A. 2000; 97: 12746–12751.
13. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. Circ Res. 1999; 85: 364–376.
14. Li YY, Kadokami T, Wang P, et al. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol. 2002; 282: H983–H989.
15. McElmurray JH III, Mukherjee R, New RB, et al. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther. 1999; 291: 799–811.
This article has been cited by other articles:
 |
|
 |
|
  K. Venkatachalam, B. Venkatesan, A. J. Valente, P. C. Melby, S. Nandish, J. E. B. Reusch, R. A. Clark, and B. Chandrasekar WISP1, a Pro-mitogenic, Pro-survival Factor, Mediates Tumor Necrosis Factor-{alpha} (TNF-{alpha})-stimulated Cardiac Fibroblast Proliferation but Inhibits TNF-{alpha}-induced Cardiomyocyte Death J. Biol. Chem., May 22, 2009; 284(21): 14414 - 14427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. McEvoy, A.-G. Taylor, J. A. Zavadzkas, I. M. Mains, R. L. Ford, R. E. Stroud, L. B. Jeffords, C. U. Beck, S. T. Reeves, and F. G. Spinale Aprotinin Exerts Differential and Dose-Dependent Effects on Myocardial Contractility, Oxidative Stress, and Cytokine Release After Ischemia-Reperfusion Ann. Thorac. Surg., August 1, 2008; 86(2): 568 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kerkela and T. Force p38 Mitogen-Activated Protein Kinase: A Future Target for Heart Failure Therapy? J. Am. Coll. Cardiol., August 1, 2006; 48(3): 556 - 558. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kaur, A. K. Sharma, and P. K. Singal Significance of changes in TNF-{alpha} and IL-10 levels in the progression of heart failure subsequent to myocardial infarction Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H106 - H113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Smookler, F. F. Mohammed, Z. Kassiri, G. S. Duncan, T. W. Mak, and R. Khokha Cutting Edge: Tissue Inhibitor of Metalloproteinase 3 Regulates TNF-Dependent Systemic Inflammation J. Immunol., January 15, 2006; 176(2): 721 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Anne, R. Willems, T. Roskams, P. Sergeant, P. Herijgers, P. Holemans, H. Ector, and H. Heidbuchel Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation Cardiovasc Res, September 1, 2005; 67(4): 655 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Kassiri, G. Y. Oudit, O. Sanchez, F. Dawood, F. F. Mohammed, R. K. Nuttall, D. R. Edwards, P. P. Liu, P. H. Backx, and R. Khokha Combination of Tumor Necrosis Factor-{alpha} Ablation and Matrix Metalloproteinase Inhibition Prevents Heart Failure After Pressure Overload in Tissue Inhibitor of Metalloproteinase-3 Knock-Out Mice Circ. Res., August 19, 2005; 97(4): 380 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ingelsson, J. Arnlov, J. Sundstrom, and L. Lind Inflammation, as Measured by the Erythrocyte Sedimentation Rate, Is an Independent Predictor for the Development of Heart Failure J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1802 - 1806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ertl and S. Frantz Healing after myocardial infarction Cardiovasc Res, April 1, 2005; 66(1): 22 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Engel, R. Peshock, R. C. Armstong, N. Sivasubramanian, and D. L. Mann Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1303 - H1311. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||